Precigen (PGEN) Share Trading at $4.02 with P/E Ratio of 9.14

Precigen, Inc. (PGEN) shares were trading at $4.02 as of April 28, with a forward P/E ratio of 9.14. The company recently transitioned to a commercial rare disease platform, following the approval of Papzimeous for recurrent respiratory papillomatosis. Market modeling predicts that by 2026, approximately 1,600–1,700 patients could be treated, rising to nearly 3,000 in 2027, which may lead to significant revenue fluctuations. Projections suggest potential quarterly earnings surprises exceeding 100% to 300% in 2026, setting the stage for notable market interest.